Last updated on October 2018

Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies


Brief description of study

The primary purpose of this study is to describe the outcome of Immune Tolerance Induction (ITI) treatment performed with rFVIIIFc within a timeframe of 60 weeks in patients with haemophilia A who have failed previous attempts at tolerization.

Detailed Study Description

This is an open-label, single-arm, interventional multi-center study designed to explore ITI performed with recombinant coagulation factor VIII Fc fusion protein (rFVIIIFc) within a timeframe of 60 weeks in patients with severe haemophilia A, who have failed previous attempts at tolerization including use of immunosuppressants.

Clinical Study Identifier: NCT03103542

Contact Investigators or Research Sites near you

Start Over

Karin Grünbaum

Swedish Orphan Biovitrum Research Site
Frankfurt am Main, Germany
7.74miles
  Connect »

Karin Grünbaum

Swedish Orphan Biovitrum Research Site
Frankfurt, Germany
7.74miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.